Pro Share Advisors LLC Acelrx Pharmaceuticals Inc Transaction History

Pro Share Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$1.03 - $1.7 $27,630 - $45,604	-26,826 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$1.25 - $2.77 $11,367 - $25,190	9,094 Added 51.29%	26,826 $46,000
Q4 2020 Feb 09, 2021	BUY	$1.18 - $1.98 $20,923 - $35,109	17,732 New	17,732 $22,000
Q3 2020 Nov 13, 2020	SELL	$1.01 - $1.81 $10,984 - $19,685	-10,876 Closed	0 $0
Q2 2020 Aug 03, 2020	BUY	$1.03 - $1.69 $11,202 - $18,380	10,876 New	10,876 $13,000
Q1 2020 May 15, 2020	SELL	$0.76 - $2.07 $8,072 - $21,987	-10,622 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$1.66 - $2.4 $32,882 - $47,541	-19,809 Reduced 65.09%	10,622 $22,000
Q3 2019 Nov 12, 2019	BUY	$2.1 - $2.87 $15,510 - $21,197	7,386 Added 32.05%	30,431 $67,000
Q2 2019 Aug 13, 2019	SELL	$2.1 - $3.93 $6,184 - $11,573	-2,945 Reduced 11.33%	23,045 $58,000
Q1 2019 May 15, 2019	BUY	$2.35 - $3.83 $11,764 - $19,172	5,006 Added 23.86%	25,990 $90,000
Q4 2018 Feb 14, 2019	BUY	$2.13 - $4.8 $44,695 - $100,723	20,984 New	20,984 $48,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.